Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$21.98 -0.6%	$20.32	$14.40 ▼ $47.00	$1.46B	1.13	955,997 shs	978,039 shs
HSKA Heska	$119.99	$119.09	$57.83 ▼ $120.03	$1.31B	1.58	241,932 shs	N/A
LNTH Lantheus	$79.21 -0.5%	$83.02	$73.11 ▼ $126.89	$5.48B	0.12	1.02 million shs	329,518 shs
MYGN Myriad Genetics	$5.60 -0.5%	$5.13	$3.81 ▼ $29.30	$516.21M	1.91	1.26 million shs	463,756 shs
VIVO Meridian Bioscience	$33.97	$33.70	$20.35 ▼ $34.38	$1.50B	0.23	973,737 shs	N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-0.61%	+3.80%	+10.59%	+39.26%	-38.81%
HSKA Heska	0.00%	0.00%	0.00%	0.00%	0.00%
LNTH Lantheus	-0.51%	-1.89%	+1.96%	-12.88%	-0.44%
MYGN Myriad Genetics	-0.53%	+5.07%	+14.75%	-31.12%	-77.56%
VIVO Meridian Bioscience	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	2.4272 of 5 stars	4.4	3.0	0.0	0.0	1.1	0.0	0.0
HSKA Heska	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	4.4562 of 5 stars	3.5	1.0	0.0	4.2	2.2	2.5	1.9
MYGN Myriad Genetics	4.2632 of 5 stars	4.1	3.0	0.0	4.1	0.6	1.7	0.6
VIVO Meridian Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	128.04% Upside
HSKA Heska	0.00	N/A	N/A	N/A
LNTH Lantheus	3.00	Buy	$130.50	64.75% Upside
MYGN Myriad Genetics	2.13	Hold	$14.38	156.87% Upside
VIVO Meridian Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest HSKA, MYGN, LNTH, CLDX, and VIVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00
5/8/2025	MYGN Myriad Genetics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	MYGN Myriad Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$18.00
5/7/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.02M	207.79	N/A	N/A	$11.26 per share	1.95
HSKA Heska	$257.31M	5.09	$1.69 per share	70.99	$39.00 per share	3.08
LNTH Lantheus	$1.53B	3.57	$7.06 per share	11.22	$15.65 per share	5.06
MYGN Myriad Genetics	$837.60M	0.62	$0.99 per share	5.63	$7.70 per share	0.73
VIVO Meridian Bioscience	$333.02M	4.49	$1.78 per share	19.13	$8.41 per share	4.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
HSKA Heska	-$19.89M	-$1.93	N/A	83.33	N/A	-7.86%	0.94%	0.67%	N/A
LNTH Lantheus	$312.44M	$3.52	22.50	12.55	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
MYGN Myriad Genetics	-$127.30M	-$1.12	N/A	N/A	N/A	-12.20%	-4.95%	-3.39%	8/5/2025 (Estimated)
VIVO Meridian Bioscience	$42.46M	$0.97	35.02	∞	N/A	12.70%	16.74%	13.09%	N/A

Latest HSKA, MYGN, LNTH, CLDX, and VIVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	-$0.03	+$0.02	N/A	$200.37 million	$195.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
HSKA Heska	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
VIVO Meridian Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	21.67	21.67
HSKA Heska	0.23	5.64	4.12
LNTH Lantheus	0.49	5.74	5.46
MYGN Myriad Genetics	0.08	1.90	1.71
VIVO Meridian Bioscience	0.07	3.63	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
HSKA Heska	99.01%
LNTH Lantheus	99.06%
MYGN Myriad Genetics	99.02%
VIVO Meridian Bioscience	89.72%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	4.40%
HSKA Heska	12.30%
LNTH Lantheus	1.50%
MYGN Myriad Genetics	2.40%
VIVO Meridian Bioscience	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
HSKA Heska	808	10.91 million	9.57 million	Not Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable
MYGN Myriad Genetics	2,700	92.18 million	89.97 million	Optionable
VIVO Meridian Bioscience	702	44.01 million	43.00 million	Optionable

HSKA, MYGN, LNTH, CLDX, and VIVO Headlines

Recent News About These Companies

Meridian Bioscience Introduces New Enzyme Stabilization Services for Molecular Diagnostics

April 24, 2025 | finance.yahoo.com

Meridian Bioscience Inc (VIVO)

April 10, 2025 | uk.investing.com

India's smartphone mkt grows 6%, Vivo tops

November 13, 2024 | rediff.comR

Meridian Bioscience Awarded Bronze Medal by EcoVadis for the Second Consecutive Year in Recognition of Its Continued Dedication to Sustainability

November 7, 2024 | finance.yahoo.com

Meridian Bioscience Gets $500K Top Prize in POC Blood Lead Test Challenge

October 28, 2024 | 360dx.com3

Precision BioSciences Launches First Hepatitis B Gene-Editing Trial

October 26, 2024 | precisionmedicineonline.comP

Will iQOO 13 launch at same price as iQOO 12? New leak provides major hint

October 25, 2024 | msn.com

Editas strengthens in vivo gene therapy strategy via $238M LNP tech pact with Genevant

October 22, 2024 | fiercebiotech.comF

Vivo and Arm collaborate on chip technology innovation, launch joint lab

October 21, 2024 | digitimes.comD

vivo and Arm collaborate on chip technology innovation with the unveiling of the vivo Arm Joint Lab

October 18, 2024 | malaysiasun.comM

Meridian Growth Legacy MERDX

October 16, 2024 | morningstar.comM

Serán Bioscience snags investment from Bain Capital Life Sciences

September 17, 2024 | pehub.com

Vivo T3 Ultra launch on September 12 – check what’s in store for India market

September 6, 2024 | financialexpress.comF

Vivo V40 vs Realme GT 6T: How the two mid-range smartphones compare

August 11, 2024 | msn.com

Fast-growing MBX Biosciences raises another $63.5 million in funding

August 6, 2024 | ibj.comI

Meridian Bioscience Leads the Way with Innovative Sustainable Solutions for in vitro Diagnostic Manufacturers

July 23, 2024 | finance.yahoo.com

Grant supports Lift Biosciences’ evaluation of IMAN cell therapies in humanized in vivo model systems

May 17, 2024 | bioworld.comB

Biomerica, Inc. (BMRA)

May 11, 2024 | finance.yahoo.com

Vivo X100s Pro with new Dimensity 9300 Plus chip could be launching soon

March 24, 2024 | gizmochina.comG

Vivo V30 Pro review: Flagship-grade imaging system in a slender form factor

March 13, 2024 | business-standard.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSKA, MYGN, LNTH, CLDX, and VIVO Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$21.98 -0.14 (-0.61%)

Closing price 07/3/2025 02:41 PM Eastern

Extended Trading

$21.28 -0.70 (-3.16%)

As of 07/3/2025 04:20 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Heska NASDAQ:HSKA

Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.

Lantheus NASDAQ:LNTH

$79.21 -0.41 (-0.51%)

Closing price 07/3/2025 03:33 PM Eastern

Extended Trading

$79.21 0.00 (0.00%)

As of 07/3/2025 04:45 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Myriad Genetics NASDAQ:MYGN

$5.60 -0.03 (-0.53%)

Closing price 07/3/2025 02:38 PM Eastern

Extended Trading

$5.60 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Meridian Bioscience NASDAQ:VIVO

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time